logo-loader
viewCo-Diagnostics

Co-Diagnostics makes coronavirus diagnostic test available to researchers

The Utah-based company has made its Logix Smart 2019-nCoV polymerase chain reaction tests immediately available on a research use only basis

People wearing medical masks
The coronavirus has killed at least 1,873 people and infected more than 72,000, according to CNN.

Co-Diagnostics Inc (NASDAQ:CODX) is doing its part to mitigate the global economic risk posed by the coronavirus by developing a diagnostic test for researchers and scientists. 

The Utah-based company has made its Logix Smart 2019-nCoV polymerase chain reaction (PCR) tests immediately available on a research use only (RUO) basis to thousands of laboratories throughout the world.

"We believe the way that Co-Diagnostics can be most helpful in this ongoing situation is by providing diagnostic solutions that are affordable and accessible in any market in the world,” CEO Dwight Egan said last week.

READ: Co-Diagnostics to showcase rapid coronavirus response at infectious disease conference in DC, closes on $10.2M offering

The coronavirus, which originated in Wuhan, China, has killed at least 1,873 people and infected more than 72,000, according to CNN.

“Our mandate includes supporting as many markets as possible in a public health crisis, and taking a test from design to commercialization in under three weeks underscores this commitment. Doing so also provides a compelling proof-of-concept that the company’s unique process and patented technology could quickly and efficiently be applied to address the diagnostic needs associated with other emergencies, including potential mutations of the coronavirus."

The company is also in discussions with regulators to gain clearance for use as an Investigational New Drug, which it believes will open doors in additional markets, including sales within the US. 

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: Co-Diagnostics

Price: 9.15 USD

NASDAQ:CODX
Market: NASDAQ
Market Cap: $227.98 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Co-Diagnostics named herein, including the promotion by the Company of Co-Diagnostics in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Co-Diagnostics expects to win a CE mark-validated...

Co-Diagnostics Inc (NASDAQ:CODX) CEO Dwight Egan tells Proactive the Utah-based company expects to achieve a CE mark validation on its coronavirus detection test from the European Union by as early as next week. Egan says the company is very enthused by the entire process of the development...

on 02/21/2020

2 min read